# EDGAR Filing Document

**Accession Number:** 0001390478
**File Stem:** 0001104659-25-114977
**Filing Date:** 2025-11
**Character Count:** 2709
**Document Hash:** 6ad14c3b206741552ab64601f6d34991
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-114977.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0001104659-25-114977

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251121

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SELLAS Life Sciences Group, Inc.
- **CENTRAL INDEX KEY:** 0001390478
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** SUITE 2503
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 6462005278

**MAIL ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** SUITE 2503
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Galena Biopharma, Inc.
- **DATE OF NAME CHANGE:** 20110926

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RXi Pharmaceuticals Corp
- **DATE OF NAME CHANGE:** 20110926

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GALENA BIOPHARMA, INC.
- **DATE OF NAME CHANGE:** 20110922

**SELLAS Life Sciences Group, Inc.**

**7 Times Square, Suite 2503**

**New York, New York 10036**

November 21, 2025

**Via** **EDGAR** 

Alan Campbell

United States Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| Re: | **SELLAS Life Sciences Group, Inc.** |

---

**Registration Statement on Form S-3**

**Filed October 10, 2025**

**File No. 333-290829**

**<u>Acceleration Request</u>**

Dear Mr. Campbell,

Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, SELLAS Life Sciences Group, Inc. (the "Registrant") hereby respectfully requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-290829), so that it may become effective at 5:00 p.m. (Washington, D.C. time) on Tuesday, November 25, 2025, or as soon thereafter as practicable.

Please call Daniel A. Bagliebter, of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any comments or questions regarding the Registration Statement.

---

| |
|:---|
| Very truly yours, |
| SELLAS Life Sciences Group, Inc. |
| /s/ Angelos M. Stergiou, M.D., Sc.D., h.c. |
| By: Angelos M. Stergiou, M.D., Sc.D., h.c. |
| Its: President and Chief Executive Officer |

---

cc: Stacy E. Yeung, Esq., *SELLAS Life Sciences Group, Inc.*

Daniel A. Bagliebter, Esq., *Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.*